Financing ·
Vivos Inc. issues Series D Preferred to board member for $250K and cancels Series C
RDGLVivos Inc
On October 7, 2026, Vivos Inc. entered into a Stock Purchase and Exchange Agreement with Carl Cadwell, a member of its Board of Directors. Pursuant to the agreement, Cadwell purchased 250,000 shares of Series D Convertible Preferred Stock for $250,000 and exchanged his existing 385,302 shares of Series C Convertible Preferred Stock for an equal number of Series D shares. The transaction was consummated on the same date, resulting in 635,302 total Series D shares outstanding with a conversion price of $0.08 per share and zero Series C shares remaining. On October 8, 2026, the company filed a Certificate of Elimination to formally cancel the Series C Convertible Preferred Stock class. Vivos Inc. operates in the biotechnology sector, focusing on cancer treatment technologies.